Skip to content


Let Healing Begin with SoftWave


SoftWave therapy is a non-invasive treatment that uses patented technology to promote healing at the cellular level, improve blood supply, and initiate the body’s natural healing process.

  • Improves blood supply and reduces inflammation
  • Patented and FDA(510k) cleared
  • 10-15 minute treatment sessions
  • Fast acting with long term results
  • No downtime, anesthesia, or numbing agents needed

Schedule a $69 new patient appointment or contact us for assistance.


Schedule a $69 new patient appointment or contact us for assistance.

Treat Apoptosis and Necrosis with An Affordable Alternative to Surgery, Injections, or Medication

Join the thousands of patients who have experienced life-changing relief from SoftWave Therapy.

Treating Apoptosis and Necrosis With SoftWave Therapy

Apoptosis and necrosis are two forms of cell death with one big difference— Apoptosis occurs naturally as part of a body’s processes while necrosis is caused by external factors.


Apoptosis and necrosis are two forms of cell death with one big difference— Apoptosis occurs naturally as part of a body’s processes while necrosis is caused by external factors.

SoftWave can be a powerful and effective treatment solution for apoptosis and necrosis. SoftWave is clinically proven with a 61% to 91% improvement in musculoskeletal and general pain complaints. It has helped thousands of patients get real lasting relief.

While apoptosis itself is not usually an issue, and in fact helps the body fight pathogens, necrosis can be catastrophic if left untreated. Necrotic tissue in a body’s organ can cause other cells to break down around them, leading to major health complications. Necrotic symptoms include:

  • Pain in the necrotic area
  • Redness and swelling
  • Blisters
  • Fluid collection
  • Skin discoloration
  • Numbness

Common causes of apoptosis and necrosis include aging, other conditions and diseases like skin cancer, infection, and external injury or trauma to the organ.

SoftWave providers can develop a plan to treat apoptosis and necrosis. With our $69 New Patient Special, you can try SoftWave today and learn if you’re a candidate for treatment.


"I feel like I have a brand new knee. I seriously feel like I could run 2 miles with no problem. Like, there's no pain. That has never happened in the last 5 months. I have never had a day where it has been like, feeling like my right knee. I'm speechless."  "I don't know why this isn't everywhere. This should be everywhere. People can heal so much faster if we had this technology." Andrew experienced knee pain for months after his surgery. Then he discovered SoftWave.


"This is the least pain I've had in probably 8 years in my whole back." Emma has been enduring scoliosis with rods on her spine since she was 15, and with SoftWave therapy she finally felt pain relief. 


"I wish we would've found you before she had surgery, you know. That probably would have prevented her having surgery." Samantha, who was suffering from paralysis from the legs down, can finally wiggle her toes after SoftWave therapy.

Shockwaves vs. Decompression and Grafting for Femoral Head Osteonecrosis

In this study comparing treatment options for osteonecrosis of the femoral head, researchers evaluated the effectiveness of noninvasive extracorporeal shock waves versus core decompression and bone-grafting. Patients with early-stage osteonecrosis were randomly assigned to either receive shock wave treatment or surgical intervention. After an average of twenty-five months, the shock-wave group showed significant improvements in pain and hip scores compared to before treatment. In this group, 79% of the hips improved, while 10% remained unchanged and 10% worsened. In contrast, the surgical group had a lower rate of improvement, with only 29% of hips showing improvement. Imaging studies also indicated regression of lesions in the shock-wave group, particularly in stage I and II cases. The findings suggest that extracorporeal shock-wave treatment may be a more effective option for early-stage osteonecrosis of the femoral head compared to surgery.

Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds

This study investigated the feasibility and safety of using extracorporeal shock wave therapy (ESWT) for complicated, nonhealing, acute and chronic soft-tissue wounds. Two hundred and eight patients were enrolled, with treatment consisting of debridement, outpatient ESWT, and moist dressings. Of the 208 patients, 156 had 100% wound epithelialization during a mean follow-up period of 44 days, and there were no treatment-related toxicities, infections, or deterioration of any ESWT-treated wound. The study concluded that ESWT is a feasible and well-tolerated strategy for treating acute and chronic soft tissue wounds.

Shockwave Therapy Reduces Wound Size by 99.9% in Elderly Patients

Alternative therapy using DermaGold soft-focused Multiwave treatment was administered to an 80-year-old patient with a large infected decubitus ulcer, resulting in a 99.9% decrease in wound size, significant healing, and nearly scar-free healthy skin tissue regeneration, demonstrating the potential of shockwave therapy as a non-invasive, pain-free option for chronic wound treatment.

New Patient Special

Try SoftWave Therapy for $69 at a clinic near you.

SoftWave FAQs

  • What is SoftWave therapy?
  • Where can I go to get SoftWave therapy?
  • What is the SoftWave treatment process like?
  • What results should I expect from SoftWave therapy?
  • Is SoftWave FDA-cleared?
  • Does SoftWave therapy have side effects?